This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v2.1.0: STU 2) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 4.0.0. For a full list of available versions, see the Directory of published versions

Value Sets

Value Sets Defined by mCODE

The following value sets are defined in this implementation guide:

• BenignUncertainNeoplasmBrainCNSDisorderVS
• BodyLocationAndLateralityQualifierVS
• BodyLocationQualifierVS
• BrachytherapyPermanentSeedsTechniqueVS
• BrachytherapyLowDoseRateTemporaryTechniqueVS
• BrachytherapyPulsedDoseRateTechniqueVS
• BrachytherapyRadiopharmaceuticalTechniqueVS
• BrachytherapyHighDoseRateElectronicTechniqueVS
• BrachytherapyHighDoseRateTechniqueVS
• BrachytherapyModalityVS
• BrachytherapyTechniqueVS
• CancerBodyLocationVS
• CancerDiseaseStatusEvidenceTypeVS
• CancerDisorderVS
• CancerRelatedSurgicalProcedureVS
• CancerStageGroupVS
• CancerStagingSystemVS
• CarcinomaInSituDisorderVS
• ClinVarVS
• ConditionStatusTrendVS
• CytologicEvidenceOfMalignancyVS
• DNAChangeTypeVS
• ElixhauserAIDSVS
• ElixhauserAlcoholAbuseVS
• ElixhauserBloodLossAnemiaVS
• ElixhauserCancerLeukemiaVS
• ElixhauserCancerLymphomaVS
• ElixhauserCancerMetastaticVS
• ElixhauserCancerSolidTumorInSituVS
• ElixhauserCancerSolidTumorMalignantVS
• ElixhauserCerebrovascularDiseaseVS
• ElixhauserChronicPulmonaryDiseaseVS
• ElixhauserCoagulationDeficiencyVS
• ElixhauserCongestiveHeartFailureVS
• ElixhauserDeficiencyAnemiaVS
• ElixhauserDementiaVS
• ElixhauserDepressionVS
• ElixhauserDiabetesComplicatedVS
• ElixhauserDiabetesUncomplicatedVS
• ElixhauserDrugAbuseVS
• ElixhauserHypertensionComplicatedVS
• ElixhauserHypertensionUncomplicatedVS
• ElixhauserHypothyroidismVS
• ElixhauserLiverDiseaseMildVS
• ElixhauserLiverDiseaseSevereVS
• ElixhauserNeurologicalMovementDisorderVS
• ElixhauserNeurologicalSeizureDisorderVS
• ElixhauserObesityVS
• ElixhauserOtherNeurologicalVS
• ElixhauserOtherThyroidDisorderVS
• ElixhauserParalysisVS
• ElixhauserPeripheralVascularDiseaseVS
• ElixhauserPsychosisVS
• ElixhauserPulmonaryCirculationDisorderVS
• ElixhauserRenalFailureModerateVS
• ElixhauserRenalFailureSevereVS
• ElixhauserRheumatoidArthritisVS
• ElixhauserUlcerVS
• ElixhauserValvularDiseaseVS
• ElixhauserWeightLossVS
• GenomicMolecularConsequenceVS
• GenomicSpecimenTypeVS
• HGNCVS
• HGVSVS
• HistologyMorphologyBehaviorVS
• HypereosinophilicSyndromeDisorderVS
• LateralityQualifierVS
• MelanomaInSituDisorderVS
• ObservationCodesDistantMetastasesVS
• ObservationCodesPrimaryTumorVS
• ObservationCodesRegionalNodesVS
• ObservationCodesStageGroupVS
• PresentAbsentVS
• PrimaryCancerDisorderVS
• PrimaryMalignantNeoplasmDisorderVS
• ProcedureIntentVS
• RadiotherapyModalityVS
• RadiotherapyTechniqueVS
• RadiotherapyTreatmentLocationQualifierVS
• RadiotherapyTreatmentLocationVS
• RadiotherapyVolumeTypeVS
• SecondaryCancerDisorderVS
• TeleradiotherapyCarbonIonBeamTechniqueVS
• TeleradiotherapyElectronBeamTechniqueVS
• TeleradiotherapyModalityVS
• TeleradiotherapyNeutronTechniqueVS
• TeleradiotherapyPhotonBeamTechniqueVS
• TeleradiotherapyProtonBeamTechniqueVS
• TeleradiotherapyTechniqueVS
• TNMDistantMetastasesCategoryVS
• TNMPrimaryTumorCategoryVS
• TNMRegionalNodesCategoryVS
• TreatmentTerminationReasonVS
• TumorMarkerTestVS
• TumorSizeMethodVS
• TumorSizeUnitsVS

External Value Sets Used in mCODE

• ACMG_Clinical significance of genetic variation
• ECOG_Performance status
• Genomic coordinate system
• Karnofsky performance status
• Medication Clinical Drug (RxNorm)
• MG_2_Genetic variant source
• MG_4_Amino acid change type
• MG_5_Genetic variant allelic state
• Structural variant analysis method